Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.
Latest Conference Articles
Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.
Advertisement
Dr. George Demetri, from Dana-Farber Cancer Institute, Discusses Regorafenib for Patients with GIST Trial Results.
Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial
Dr. Mathias Rummel, from University Hospital Giessen in Germany, on Bendamustine Plus Rituximab in Indolent and Mantle Cell Lymphomas
Dr. Eric Pujade-Lauraine, from Université de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.
Advertisement
Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558
Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on Dabrafenib and Trametinib Combination Side Effects
American Society of Clinical Oncology (ASCO) 2012 Annual Meeting video highlights, from OncLive TV.
Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.
Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on the Unique Attributes of Neoadjuvant Zytiga.
Dr. Paul W. Ladenson, from Johns Hopkins Medicine, on Diagnosis of Thyroid Nodules
Photos taken from the AACE 21st Annual Scientific and Clinical Congress held at the Pennsylvania Convention Center, from May 23-27, 2012.
Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on the Dabrafenib Plus Trametinib Combination for Melanoma
Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate
Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma
Dr. Maurie Markman, Cancer Treatment Centers of America, on Primary Care Physician Awareness of Long-Term Chemotherapy Side Effects
Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL
Dr. Shayma Kazmi, from Cancer Treatment Centers of America, on Olanzapine for Breakthrough Chemotherapy-Induced Nausea and Vomiting
Five nurses discuss the value of the Oncology Nursing Society (ONS) Annual Congress, which is the largest meeting held specifically for oncology nurses.
The Oncology Nursing Society (ONS) 37th Annual Congress video highlights, from OncLive TV.
The Oncology Nursing Society (ONS) 37th Annual Congress Picture Slideshow.
Mary Gullatte, the president of the Oncology Nursing Society, Discusses Nursing Shortages
Carol Bush, BS, RN, from the The University of Kansas Cancer Center, on the Midwest Cancer Alliance Telehealth Network
Erin McMenamin, MSN, from the Hospital of the University of Pennsylvania, on HPV-related Head & Neck Cancer Prognosis
Krista Rubin, MS, RN, FNP-BC, from Massachusetts General Hospital Cancer Center, on Managing Ipilimumab-related Dermatitis.
Michael Eckenfels, RN, OCN, from MD Anderson Cancer Center, on Changes to the Bortezomib Delivery Route.
Anna Vioral, RN, OCN, from West Penn Allegheny Health System, on Multidisciplinary Chemotherapy Safety Standards.
Anne Katz, from the University of Manitoba, Discusses Cancer and Sexuality
Jayshree Shah, from John Theurer Cancer Center, on the Safety and Efficacy of Nilotinib for Patients With CML
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5